v3.26.3
Interim Condensed Consolidated Balance Sheets - Chemomab Therapeutics Ltd [Member] - USD ($)
$ in Thousands
Jun. 30, 2026
Dec. 31, 2025
Dec. 31, 2024
Current assets      
Cash and cash equivalents $ 5,999 $ 7,564 $ 6,071
Short term bank deposits 688 2,802 8,195
Restricted cash   76
Other receivables and prepaid expenses 3,270 3,059 1,698
Total current assets 9,957 13,425 16,040
Non-current assets      
Long term prepaid expenses 123 211 385
Property and equipment, net 158 176 250
Operating lease right-of-use assets   289
Total non-current assets 281 387 924
Total assets 10,238 13,812 16,964
Current liabilities      
Trade payables 257 485 633
Accrued expenses 493 337 [1] 1,536 [1]
Employees and related expenses 803 656 [2] 934 [2]
Operating lease liabilities   115
Total current liabilities 1,553 1,478 3,218
Non-current liabilities      
Non-current operating lease liabilities   209
Total non-current liabilities   209
Commitments and contingent liabilities    
Total liabilities 1,553 1,478 3,427
Shareholders’ equity (*)      
Ordinary share value [3] [4] [4]
Additional paid in capital 124,241 [3] 123,952 [3] 116,160
Accumulated deficit (115,556) [3] (111,618) [3] (102,623)
Total shareholders’ equity 8,685 [3] 12,334 [3] 13,537
Total liabilities and shareholders’ equity $ 10,238 [3] $ 13,812 [3] $ 16,964
[1] Includes balances due to related parties of $74 thousand and $75 thousand as of December 31, 2025 and 2024, respectively. See Note 12.
[2] Includes balances due to related parties of $458 thousand and $531 thousand as of December 31, 2025 and 2024, respectively. See Note 12.
[3] 1 American Depositary Share (ADS) represents 80 Ordinary Shares.
[4] 1 American Depositary Share (ADS) represents 80 Ordinary Shares.